Optimer Dificid FDA Approval for C. Diff Hinges on How to Describe Lasting Effect
This article was originally published in RPM Report
Optimer’s Dificid (fidaxomicin) oral tablets for C. difficile received a strong endorsement from the Food & Drug Administration’s Anti-Infective Drugs Advisory Committee on April 5. Final approval of Optimer’s application awaits resolution of labeling language regarding the drug’s ability to deter recurrence of C. difficile infections. The drug has an initial (priority review) PDUFA date of May 30.
You may also be interested in...
Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
FDA’s effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms.
Ceftaroline: A Success for Biomarker Development
The regulatory environment for anti-infective approvals is getting better: that is one message from the positive FDA advisory committee review of Forest’s ceftaroline. A corollary message is that the work on biomarkers and improved endpoints (by groups outside FDA) is having an impact.
Antibiotic Early Endpoints: FDA Looking At Patient Observations
An effort to identify early biomarkers of antibiotic efficacy is turning toward patient assessments of drug activity. FDA and industry scientists are both participating in the biomarker effort. The attention to patient observations reflects a growing interest at FDA.